Shalby Limited — Investor Meet, 11-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Shalby Limited reported consolidated revenues of Rs. 281 crore for Q3 FY25, a 27.4% increase year-over-year from Rs. 221 crore. However, the EBITDA fell from Rs. 46.8 crore last year to Rs. 39.3 crore this quarter, reflecting a margin contraction to 14% from 21.2%. The profit before tax (PBT) declined to Rs. 12.4 crore, resulting in a margin of 4.4%, down from 14%. For the nine-month period, total revenue reached Rs. 844 crore, up 19.9% year-over-year. The standalone hospital business saw revenue growth of 13.3%, reaching Rs. 227 crore.

2. **Future Outlook and Growth Drivers:** Management emphasized a strong commitment to enhancing clinical excellence and expanding capacity in key areas, particularly oncology and implant businesses. Plans are in place for operational optimization and new product launches, including robotic surgeries.

3. **Order Book and Operational Updates:** The implant business experienced significant revenue growth of 58% year-over-year, generating Rs. 22.6 crore. The total constructs sold increased by 16%. Operationally, Shalby continues to invest in strategic growth areas, including international market penetration and expansion of service offerings.

4. **Analyst Q&A Insights:**

- **Revenue and Profitability:** Analysts probed into profitability trends, with management providing clarity on expected improvements in EBITDA margins and the impact of operational efficiencies.

- **Market Position and Competitive Landscape:** Questions focused on competitive pressures within the oncology segment, with management confident in their market positioning due to a robust pipeline of new products and operational capabilities.

- **Operational Challenges or Risks:** Key concerns included supply chain durability and market saturation. Management expressed optimism about mitigating these risks through strategic partnerships and cost control.

- **Capex and Capital Allocation:** Queries about capex plans highlighted an ongoing commitment to expand bed capacity and modernization at existing facilities, with capital expenditures anticipated to support growth.

- **Strategic Priorities and Long-Term Vision:** Analysts sought clarification on long-term growth strategies, linking these to healthcare trends and technological advancements.

5. **Market or Regulatory Updates:** There were no significant regulatory updates discussed that would impact future strategies, though increasing adoption of health technologies was noted as a potential growth field.

6. **Strategic Focus Areas:** Management's focus remains on clinical excellence, cost control, and market expansion, particularly through technological integration in surgical procedures.

7. **Investor Insight:** The financial health showcases signs of steady growth potential, especially with planned expansions and strong sales in the implant segment. Sustainable profit growth and ongoing demand in healthcare suggest a favorable outlook for stakeholders. Overall, the observed performance and strategic direction may align with a buy position for retail investors.